Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction

AIMS: No biomarker has achieved widespread acceptance as a surrogate endpoint for early‐phase heart failure (HF) trials. We assessed whether changes over time in a panel of plasma biomarkers were associated with subsequent morbidity/mortality in HF with reduced ejection fraction (HFrEF). METHODS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Savarese, Gianluigi, Uijl, Alicia, Ouwerkerk, Wouter, Tromp, Jasper, Anker, Stefan D., Dickstein, Kenneth, Hage, Camilla, Lam, Carolyn S.P., Lang, Chim C., Metra, Marco, Ng, Leong L., Orsini, Nicola, Samani, Nilesh J., van Veldhuisen, Dirk J., Cleland, John G.F., Voors, Adriaan A., Lund, Lars H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288797/
https://www.ncbi.nlm.nih.gov/pubmed/35388650
http://dx.doi.org/10.1002/ehf2.13917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288797/
https://www.ncbi.nlm.nih.gov/pubmed/35388650
http://dx.doi.org/10.1002/ehf2.13917

Ejemplares similares